

**Clinical Policy: Motixafortide (Aphexda)**

Reference Number: CP.PHAR.655

Effective Date: 12.01.23

Last Review Date: 11.25

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Description**

Motixafortide (Aphexda<sup>®</sup>) is a hematopoietic stem cell mobilizer.

**FDA Approved Indication(s)**

Aphexda is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma (MM).

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Aphexda is **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria****A. Mobilization of Hematopoietic Stem Cells (must meet all):**

1. Diagnosis of MM;
2. Prescribed by or in consultation with an oncologist, hematologist, or transplant specialist;
3. Age  $\geq$  18 years;
4. Prescribed in combination with a formulary G-CSF (i.e., Zarxio<sup>®</sup>);  
*\*Prior authorization may be required for G-CSF.*
5. Member is scheduled to receive autologous stem cell transplantation;
6. Failure of plerixafor, unless contraindicated or clinically significant adverse effects are experienced;\*  
*\*For Illinois HIM requests, the step therapy requirements above do not apply as of 1/1/2026 per IL HB 5395*
7. Dose does not exceed one of the following (a or b):
  - a. Request meets both of the following (i and ii):
    - i. Dose does not exceed 1.25 mg per kg of actual body weight;
    - ii. Aphexda is prescribed to be administered for up to 2 doses per autologous stem cell transplantation;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration: 3 months**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Mobilization of Hematopoietic Stem Cells**

1. Re-authorization is not permitted. Members must meet the initial approval criteria.  
**Approval duration: Not applicable**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

#### IV. Appendices/General Information

##### *Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

G-CSF: granulocyte-colony stimulating factor

HSCs: hematopoietic stem cells

MM: multiple myeloma

##### *Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

| Drug Name                | Dosing Regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Dose Limit/<br>Maximum Dose |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| plerixafor<br>(Mozobil®) | <p>The recommended dose of Mozobil by SC injection is based on actual body weight:</p> <ul style="list-style-type: none"> <li>• ≤ 83 kg: 20 mg fixed dose or 0.24 mg/kg of body weight</li> <li>• &gt; 83 kg: 0.24 mg/kg of body weight</li> </ul> <p>Initiate Mozobil treatment after the patient has received G-CSF once daily for 4 days. Administer Mozobil approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days.</p> <p>Use actual body weight to calculate the volume of Mozobil to be administered:<br/> <math>0.012 \times \text{actual body weight (in kg)} = \text{volume to be administered (in mL)}</math>.</p> <p>Mozobil dose and treatment if weight is more than 175% of ideal body weight have not been investigated.</p> | 40 mg/day                   |

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

##### *Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): history of serious hypersensitivity reaction to Aphexda
- Boxed warning(s): none reported

#### V. Dosage and Administration

| Indication | Dosing Regimen                                                    | Maximum Dose       |
|------------|-------------------------------------------------------------------|--------------------|
| MM         | The recommended dose of Aphexda is 1.25 mg/kg actual body weight. | See dosing regimen |

| Indication | Dosing Regimen                                                                                                                                                                                                                                                                                                                             | Maximum Dose |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
|            | Initiate Aphexda treatment after filgrastim has been administered daily for 4 days. Administer Aphexda via slow (approximately 2 minutes) subcutaneous injection 10 to 14 hours prior to the initiation of the first apheresis.<br><br>A second dose of Aphexda can be administered 10 to 14 hours before a third apheresis, if necessary. |              |

## VI. Product Availability

Single-dose vial for injection: 62 mg of motixafortide as a lyophilized power for reconstitution

## VII. References

1. Aphexda Prescribing Information. Waltham, MA: BioLineRx; May 2025. Available at: [www.aphexda.com](http://www.aphexda.com). Accessed July 17, 2025.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: [https://www.nccn.org/professionals/drug\\_compendium/content/](https://www.nccn.org/professionals/drug_compendium/content/). Accessed August 4, 2025.
3. National Comprehensive Cancer Network. Hematopoietic Cell Transplantation Version 2.2025. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/hct.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hct.pdf). Accessed August 4, 2025.

## Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| HCPSC Codes | Description                       |
|-------------|-----------------------------------|
| J2277       | Injection, motixafortide, 0.25 mg |

| Reviews, Revisions, and Approvals                                                                                                                                | Date     | P&T Approval Date |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|-------------------|
| Policy created                                                                                                                                                   | 09.29.23 | 11.23             |
| Added redirection to plerixafor.                                                                                                                                 | 11.28.23 | 02.24             |
| Added HCPCS code [J2277] and removed HCPCS codes [C3590, C9399].                                                                                                 | 02.22.24 |                   |
| 4Q 2024 annual review: no significant changes; references reviewed and updated.                                                                                  | 07.15.24 | 11.24             |
| 4Q 2025 annual review: added transplant specialist as a prescriber option; added step therapy bypass for IL HIM per IL HB 5395; references reviewed and updated. | 08.04.25 | 11.25             |

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members, and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2023 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.